Table 2.

Ten-year risk of death with 95% CI for clinicopathologic characteristics stratified by cause of death

Clinicopathologic characteristicsLymphoma-related deathNon–lymphoma-related deathUnknown death
10-y estimate95% CIP10-y estimate95% CIP10-y estimate95% CIP
All 0.080 0.062-0.104  0.136 0.112-0.166  0.045 0.032-0.065  
Age group, y   <.001   <.001   <.001 
 ≤60 0.041 0.023-0.075  0.055 0.033-0.093  0.017 0.007-0.040  
 61-70 0.068 0.042-0.109  0.137 0.096-0.196  0.031 0.015-0.065  
 70+ 0.148 0.105-0.208  0.245 0.190-0.315  0.100 0.064-0.156  
Sex   .122   .060   .184 
 Male 0.097 0.070-0.133  0.146 0.113-0.188  0.050 0.032-0.078  
 Female 0.064 0.042-0.097  0.127 0.093-0.172  0.041 0.023-0.073  
LDH group   .001   .971   .628 
 ≤Normal 0.065 0.046-0.092  0.144 0.114-0.182  0.042 0.026-0.065  
 >Normal 0.158 0.103-0.243  0.154 0.095-0.251  0.072 0.033-0.157  
HGB group   .001   .009   .826 
 ≥12 g/dL 0.061 0.041-0.090  0.115 0.086-0.154  0.048 0.030-0.077  
 <12 g/dL 0.136 0.096-0.194  0.199 0.149-0.266  0.048 0.027-0.086  
Ann Arbor stage   <.001   .013   .050 
 I-II 0.022 0.009-0.054  0.094 0.063-0.141  0.031 0.015-0.066  
 III-IV 0.114 0.087-0.149  0.151 0.120-0.191  0.056 0.038-0.084  
IPI score   <.001   <.001   .069 
 0-1 0.038 0.021-0.069  0.081 0.055-0.119  0.028 0.014-0.056  
 2 0.093 0.061-0.144  0.159 0.116-0.218  0.054 0.030-0.095  
 3 0.147 0.098-0.220  0.195 0.134-0.286  0.060 0.030-0.117  
 4-5 0.181 0.086-0.379  0.312 0.169-0.576  0.140 0.041-0.471  
FLIPI group   <.001   <.001   .045 
 FLIPI 0-1 0.023 0.011-0.048  0.085 0.057-0.125  0.030 0.015-0.059  
 FLIPI 2 0.098 0.064-0.150  0.145 0.103-0.202  0.048 0.026-0.089  
 FLIPI 3-5 0.168 0.120-0.237  0.223 0.165-0.302  0.073 0.041-0.131  
MALTIPI group   <.001   <.001   .001 
 MALTIPI 0 0.013 0.003-0.052  0.033 0.015-0.073  0.016 0.005-0.048  
 MALTIPI 1 0.054 0.033-0.087  0.160 0.121-0.211  0.038 0.021-0.069  
 MALTIPI 2-3 0.180 0.134-0.243  0.190 0.143-0.253  0.084 0.052-0.136  
Initial treatment   .001   .445   .419 
 Observation 0.075 0.049-0.116  0.160 0.119-0.214  0.035 0.018-0.068  
 R-Mono therapy 0.124 0.070-0.219  0.121 0.071-0.209  0.047 0.020-0.112  
 ImmunoChemo therapy 0.131 0.082-0.208  0.141 0.089-0.222  0.059 0.030-0.116  
 Radiation therapy 0.000 Not applicable  0.073 0.033-0.161  0.026 0.006-0.105  
 Other 0.063 0.033-0.119  0.135 0.084-0.217  0.065 0.030-0.140  
EFS 24   <.001   .369   .776 
 Achieved 0.051 0.033-0.078  0.153 0.121-0.192  0.046 0.030-0.073  
 Failed 0.191 0.128-0.285  0.110 0.065-0.187  0.050 0.022-0.113  
Histologic type   <.001   .030   .132 
 EMZL 0.037 0.022-0.064  0.106 0.076-0.149  0.035 0.019-0.064  
 LGBCL-U 0.110 0.070-0.172  0.185 0.132-0.259  0.069 0.037-0.131  
 LPL 0.193 0.117-0.318  0.089 0.044-0.183  0.038 0.012-0.117  
 NMZL 0.052 0.020-0.135  0.095 0.043-0.208  0.015 0.002-0.107  
 SMZL 0.103 0.052-0.204  0.230 0.149-0.354  0.071 0.033-0.155  
Clinicopathologic characteristicsLymphoma-related deathNon–lymphoma-related deathUnknown death
10-y estimate95% CIP10-y estimate95% CIP10-y estimate95% CIP
All 0.080 0.062-0.104  0.136 0.112-0.166  0.045 0.032-0.065  
Age group, y   <.001   <.001   <.001 
 ≤60 0.041 0.023-0.075  0.055 0.033-0.093  0.017 0.007-0.040  
 61-70 0.068 0.042-0.109  0.137 0.096-0.196  0.031 0.015-0.065  
 70+ 0.148 0.105-0.208  0.245 0.190-0.315  0.100 0.064-0.156  
Sex   .122   .060   .184 
 Male 0.097 0.070-0.133  0.146 0.113-0.188  0.050 0.032-0.078  
 Female 0.064 0.042-0.097  0.127 0.093-0.172  0.041 0.023-0.073  
LDH group   .001   .971   .628 
 ≤Normal 0.065 0.046-0.092  0.144 0.114-0.182  0.042 0.026-0.065  
 >Normal 0.158 0.103-0.243  0.154 0.095-0.251  0.072 0.033-0.157  
HGB group   .001   .009   .826 
 ≥12 g/dL 0.061 0.041-0.090  0.115 0.086-0.154  0.048 0.030-0.077  
 <12 g/dL 0.136 0.096-0.194  0.199 0.149-0.266  0.048 0.027-0.086  
Ann Arbor stage   <.001   .013   .050 
 I-II 0.022 0.009-0.054  0.094 0.063-0.141  0.031 0.015-0.066  
 III-IV 0.114 0.087-0.149  0.151 0.120-0.191  0.056 0.038-0.084  
IPI score   <.001   <.001   .069 
 0-1 0.038 0.021-0.069  0.081 0.055-0.119  0.028 0.014-0.056  
 2 0.093 0.061-0.144  0.159 0.116-0.218  0.054 0.030-0.095  
 3 0.147 0.098-0.220  0.195 0.134-0.286  0.060 0.030-0.117  
 4-5 0.181 0.086-0.379  0.312 0.169-0.576  0.140 0.041-0.471  
FLIPI group   <.001   <.001   .045 
 FLIPI 0-1 0.023 0.011-0.048  0.085 0.057-0.125  0.030 0.015-0.059  
 FLIPI 2 0.098 0.064-0.150  0.145 0.103-0.202  0.048 0.026-0.089  
 FLIPI 3-5 0.168 0.120-0.237  0.223 0.165-0.302  0.073 0.041-0.131  
MALTIPI group   <.001   <.001   .001 
 MALTIPI 0 0.013 0.003-0.052  0.033 0.015-0.073  0.016 0.005-0.048  
 MALTIPI 1 0.054 0.033-0.087  0.160 0.121-0.211  0.038 0.021-0.069  
 MALTIPI 2-3 0.180 0.134-0.243  0.190 0.143-0.253  0.084 0.052-0.136  
Initial treatment   .001   .445   .419 
 Observation 0.075 0.049-0.116  0.160 0.119-0.214  0.035 0.018-0.068  
 R-Mono therapy 0.124 0.070-0.219  0.121 0.071-0.209  0.047 0.020-0.112  
 ImmunoChemo therapy 0.131 0.082-0.208  0.141 0.089-0.222  0.059 0.030-0.116  
 Radiation therapy 0.000 Not applicable  0.073 0.033-0.161  0.026 0.006-0.105  
 Other 0.063 0.033-0.119  0.135 0.084-0.217  0.065 0.030-0.140  
EFS 24   <.001   .369   .776 
 Achieved 0.051 0.033-0.078  0.153 0.121-0.192  0.046 0.030-0.073  
 Failed 0.191 0.128-0.285  0.110 0.065-0.187  0.050 0.022-0.113  
Histologic type   <.001   .030   .132 
 EMZL 0.037 0.022-0.064  0.106 0.076-0.149  0.035 0.019-0.064  
 LGBCL-U 0.110 0.070-0.172  0.185 0.132-0.259  0.069 0.037-0.131  
 LPL 0.193 0.117-0.318  0.089 0.044-0.183  0.038 0.012-0.117  
 NMZL 0.052 0.020-0.135  0.095 0.043-0.208  0.015 0.002-0.107  
 SMZL 0.103 0.052-0.204  0.230 0.149-0.354  0.071 0.033-0.155  
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal